Pathology & Lab Medicine Knowledge & Practice

• 10.25 90.25
  What's Your Take? Perspectives on Immunotherapy for Early-Stage Solid Tumors
  Medscape Education Oncology February 23, 2023
  Did you know? Immunotherapy is now being used for the neoadjuvant and adjuvant treatment of solid tumors -- find out more here!
  
  0.25 CMEMIN 0.25 ABIM MOCMIN

  
  Save
• 10.50 90.50
  What’s New in Cholangiocarcinoma: Updates From the Annual American Gastrointestinal Cancer Symposium
  Medscape Education Oncology February 22, 2023
  Are you up to date on the latest data on the management of cholangiocarcinoma and how it applies to clinical practice?
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 11.25 91.25
  Harnessing the Power of Emerging Therapies in the Management of Patients With Pancreatic Cancer
  Medscape Education Oncology February 08, 2023
  Did you know that pancreatic cancer remains a deadly condition that is often not discovered until the metastatic stage?
  
  1.25 CMEMIN 1.25 ABIM MOCMIN

  
  Save
• 10.75 90.75
  EGFR Expansion: Optimizing EGFR Identification Across the Spectrum of Non-Small Cell Lung Cancer
  Medscape Education Pathology January 31, 2023
  How do you approach testing and treatment of patients with EGFR mutations? Join here for a multidisciplinary perspective.
  
  0.75 CMEMIN 0.75 ABIM MOCMIN

  
  Save
• 10.75 90.75 20.75 30.75
  Acute Myeloid Leukemia and the Role of FLT3 Inhibitors: Best Practices for the Interprofessional Care Team
  Medscape Education Oncology January 30, 2023
  What’s new in FLT3 acute myeloid leukemia (AML)? Join to hear a panel of experts discuss how they use FLT3 inhibitors in patients with AML.
  
  0.75 CME/CEMIN 0.75 ABIM MOCMIN 0.75 CEMIN 0.75 CEMIN

  
  Save
• 10.50 90.50
  Ovarian Cancer Consult: Adapting to PARP Inhibitors
  Medscape Education Ob/Gyn & Women's Health January 20, 2023
  Three case studies illustrate the use of poly(ADP-ribose) polymerase (PARP) inhibitors in the management of ovarian cancer.
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 10.50 90.50
  Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myeloproliferative Neoplasms: Spotlight on New Data From New Orleans 2022
  Medscape Education Oncology January 18, 2023
  Catch up on the biggest news in AML, MDS, and MPNs from the 2022 Winter Hematology meeting.
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 10.25 90.25
  Assess Your Understanding of Immune Checkpoint Inhibitors in Metastatic Melanoma
  Medscape Education Oncology January 13, 2023
  Did you know that melanoma has more somatic mutations than any other cancer type?
  
  0.25 CMEMIN 0.25 ABIM MOCMIN

  
  Save
• 10.50 90.50
  Endometrial Cancer Consult: Optimal Management Across the Disease Continuum
  Medscape Education Oncology January 10, 2023
  Do you know the best management strategies and the latest clinical data for advanced endometrial cancer (EC)?
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 10.50
  Managing Relapsed/Refractory Multiple Myeloma: The Ever-Expanding Role of B-Cell Maturation Antigen as a Molecular Target
  Medscape Education Oncology December 30, 2022
  Did you know that B-cell maturation antigen (BCMA) is heavily present on myeloma cells, meaning that BCMA-targeted therapy could help slow the growth of myeloma?
  
  0.50 CMEMIN

  
  Save
• 10.50 90.50
  The New Climate of Bruton Tyrosine Kinase Inhibitors: Winter Meeting Effects on the Management of CLL and MCL
  Medscape Education December 30, 2022
  Did you know that the second-generation Bruton tyrosine kinase (BTK) inhibitors will likely be the new standard of care when used as monotherapy?
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 11.50 91.50 21.50 31.50
  Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome
  Medscape Education Oncology December 29, 2022
  Are you able to risk stratify and personalize treatment for patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS)?
  
  1.50 CME/CEMIN 1.50 ABIM MOCMIN 1.50 CEMIN 1.50 CEMIN

  
  Save
• 10.50 90.50
  BTK Inhibitors for CLL and MCL: A Settling Storm or Just the Beginning?
  Medscape Education Oncology December 28, 2022
  Did you know that emerging noncovalent BTK inhibitors could fill the gap for patients with B-cell malignancies who fail covalent BTK inhibitors?
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 11.50 91.50 21.50 31.50
  Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic
  Medscape Education Oncology December 27, 2022
  How can clinicians utilize a more tailored approach to selecting treatment for multiple myeloma (MM)?
  
  1.50 CME/CEMIN 1.50 ABIM MOCMIN 1.50 CEMIN 1.50 CEMIN

  
  Save
• 10.75 90.75 20.75
  Improving Outcomes and Quality of Life in Advanced GIST: Discussing the Patient Journey and the Latest Data
  Medscape Education Oncology December 19, 2022
  Are you up to date on the latest data on tyrosine kinase inhibitors (TKIs) in the management of gastrointestinal stromal tumors (GISTs)? Do you know how to leverage the interprofessional team to empower patients?
  
  0.75 CME/CEMIN 0.75 ABIM MOCMIN 0.75 CEMIN

  
  Save
• 11.25 91.25
  A Clinical Case Symposium: Targeted Therapies in HER2-Positive Breast Cancer
  Medscape Education Oncology December 09, 2022
  Join this discussion to hear our experts discuss the management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer across multiple lines of therapy.
  
  1.25 CMEMIN 1.25 ABIM MOCMIN

  
  Save
• 11.25 91.25
  A Clinical Case Symposium: New Therapies in Early Breast Cancer
  Medscape Education Oncology December 09, 2022
  Join this discussion to hear our experts discuss the incorporation of targeted agents into the treatment of early breast cancer.
  
  1.25 CMEMIN 1.25 ABIM MOCMIN

  
  Save
• 12.00 92.00 22.00 32.00
  Metastatic Disease Considerations in Triple Negative Breast Cancer
  Medscape Education Oncology December 08, 2022
  Are you up to date on optimal strategies for managing metastatic triple-negative breast cancer (mTNBC)?
  
  2.00 CME/CEMIN 2.00 ABIM MOCMIN 2.00 CEMIN 2.00 CEMIN

  
  Save
• 12.50 92.50 22.50
  PET Imaging and Beyond
  Medscape Education Radiology December 08, 2022
  How is your imaging practice informing treatment and improving outcomes for patients with breast cancer?
  
  2.50 CME/CEMIN 2.50 ABIM MOCMIN 2.50 CEMIN

  
  Save
• 10.25
  Winter Conference Forecast for CLL and MCL: An Expert Exchange on Bruton Tyrosine Kinase Inhibitors
  Medscape Education December 02, 2022
  Did you know that exciting data on covalent and non-covalent Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are being presented at the upcoming winter conference?
  
  0.25 CMEMIN

  
  Save